Cargando…

Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan

BACKGROUND: Aripiprazole is a third-generation antipsychotic agent with acceptable efficacy and a good safety profile. Previous studies have indicated the therapeutic serum concentration of aripiprazole to be 100 to 350 ng/ml; however, most of these studies examined a Western population. Patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tien, Yun, Huang, Hsiang-Ping, Liao, Ding-Lieh, Huang, Shang-Chien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340887/
https://www.ncbi.nlm.nih.gov/pubmed/35923249
http://dx.doi.org/10.1177/20451253221113238
_version_ 1784760493253066752
author Tien, Yun
Huang, Hsiang-Ping
Liao, Ding-Lieh
Huang, Shang-Chien
author_facet Tien, Yun
Huang, Hsiang-Ping
Liao, Ding-Lieh
Huang, Shang-Chien
author_sort Tien, Yun
collection PubMed
description BACKGROUND: Aripiprazole is a third-generation antipsychotic agent with acceptable efficacy and a good safety profile. Previous studies have indicated the therapeutic serum concentration of aripiprazole to be 100 to 350 ng/ml; however, most of these studies examined a Western population. Patients with schizophrenia from Tungs’ Taichung MetroHarbor Hospital in central Taiwan were recruited to analyze the dose–response relationship of aripiprazole in the Chinese population. OBJECTIVE: We aimed to investigate whether a serum concentration of aripiprazole higher than the current suggested range leads to higher response rates. DESIGN: A prospective cohort study was designed to investigate the response rates in different studied cohorts grouped by serum concentration of aripiprazole. DATA SOURCES AND METHODS: Data of 64 patients who presented to a single medical center in central Taiwan and who received therapeutic drug monitoring (TDM) were obtained. Serum concentrations of aripiprazole were correlated with the clinical response of patients by using the Clinical Global Impressions (CGI) scores. RESULTS: The mean concentration of aripiprazole was 432.1 ± 275.1 ng/ml in the study cohort. Among the much-improved patients, the mean serum concentration of aripiprazole was 494 ± 273 ng/ml (25th–75th percentiles 264–666 ng/ml), which was higher than the current recommended therapeutic target of 100–350 ng/ml for aripiprazole. The response rate in the severe group (baseline CGI score of 6 or 7) was significantly higher than in the moderate group (baseline CGI score of 4 or 5; 86.7% versus 55.9%, p = 0.007). CONCLUSION: A significantly higher response rate was observed in the study cohort with serum aripiprazole concentrations over 300 ng/ml. Therefore, dosing higher than the current recommended range may potentially improve the treatment efficacy in the Chinese population. Because the serum concentration varies among patients due to multiple intrinsic and extrinsic factors, TDM, especially in outpatients, is recommended if the clinical response is limited.
format Online
Article
Text
id pubmed-9340887
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-93408872022-08-02 Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan Tien, Yun Huang, Hsiang-Ping Liao, Ding-Lieh Huang, Shang-Chien Ther Adv Psychopharmacol Original Research BACKGROUND: Aripiprazole is a third-generation antipsychotic agent with acceptable efficacy and a good safety profile. Previous studies have indicated the therapeutic serum concentration of aripiprazole to be 100 to 350 ng/ml; however, most of these studies examined a Western population. Patients with schizophrenia from Tungs’ Taichung MetroHarbor Hospital in central Taiwan were recruited to analyze the dose–response relationship of aripiprazole in the Chinese population. OBJECTIVE: We aimed to investigate whether a serum concentration of aripiprazole higher than the current suggested range leads to higher response rates. DESIGN: A prospective cohort study was designed to investigate the response rates in different studied cohorts grouped by serum concentration of aripiprazole. DATA SOURCES AND METHODS: Data of 64 patients who presented to a single medical center in central Taiwan and who received therapeutic drug monitoring (TDM) were obtained. Serum concentrations of aripiprazole were correlated with the clinical response of patients by using the Clinical Global Impressions (CGI) scores. RESULTS: The mean concentration of aripiprazole was 432.1 ± 275.1 ng/ml in the study cohort. Among the much-improved patients, the mean serum concentration of aripiprazole was 494 ± 273 ng/ml (25th–75th percentiles 264–666 ng/ml), which was higher than the current recommended therapeutic target of 100–350 ng/ml for aripiprazole. The response rate in the severe group (baseline CGI score of 6 or 7) was significantly higher than in the moderate group (baseline CGI score of 4 or 5; 86.7% versus 55.9%, p = 0.007). CONCLUSION: A significantly higher response rate was observed in the study cohort with serum aripiprazole concentrations over 300 ng/ml. Therefore, dosing higher than the current recommended range may potentially improve the treatment efficacy in the Chinese population. Because the serum concentration varies among patients due to multiple intrinsic and extrinsic factors, TDM, especially in outpatients, is recommended if the clinical response is limited. SAGE Publications 2022-07-30 /pmc/articles/PMC9340887/ /pubmed/35923249 http://dx.doi.org/10.1177/20451253221113238 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Tien, Yun
Huang, Hsiang-Ping
Liao, Ding-Lieh
Huang, Shang-Chien
Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan
title Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan
title_full Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan
title_fullStr Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan
title_full_unstemmed Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan
title_short Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan
title_sort dose-response analysis of aripiprazole in patients with schizophrenia in taiwan
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340887/
https://www.ncbi.nlm.nih.gov/pubmed/35923249
http://dx.doi.org/10.1177/20451253221113238
work_keys_str_mv AT tienyun doseresponseanalysisofaripiprazoleinpatientswithschizophreniaintaiwan
AT huanghsiangping doseresponseanalysisofaripiprazoleinpatientswithschizophreniaintaiwan
AT liaodinglieh doseresponseanalysisofaripiprazoleinpatientswithschizophreniaintaiwan
AT huangshangchien doseresponseanalysisofaripiprazoleinpatientswithschizophreniaintaiwan